Sarepta Therapeutics (SRPT) PT Lowered to $75 at Needham & Company; 'FY17 Guidance Significantly Below Expectations'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. S
10. COF

Go back to Sarepta Therapeutics (SRPT) PT Lowered to $75 at Needham & Company; 'FY17 Guidance Significantly Below Expectations'

Instinet Starts Sarepta Therapeutics (SRPT) at Buy, $84 PT

March 1, 2017 4:24 PM EST

Instinet initiates coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Buy rating and a price target of $84.00.

Analyst Christopher Marai commented, "We are initiating coverage on Sarepta Therapeutics (SRPT) with a Buy rating and $84 target price. We recommend owning SRPT shares, expecting significant... More

Sarepta Therapeutics (SRPT) Sees Strong Red-to-Green Reversal

March 1, 2017 11:17 AM EST

Sarepta Therapeutics (NASDAQ: SRPT) reverses large after-hours losses and goes positive as CMS update adds pass-thru drug code C9484 or Eteplirsen. LINK

Shares are up 1.4%.

... More